Novel Digital Application for Patients With Acute Leukemia

Launched by MASSACHUSETTS GENERAL HOSPITAL · Jun 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new digital application called DREAMLAND, designed to help improve the quality of life and mental well-being of adults with acute myeloid leukemia (AML) who are receiving intensive chemotherapy. The goal is to see if using this app can make a positive difference in how patients feel during and after their treatment.

To participate in this study, you need to be at least 18 years old and currently hospitalized for AML, starting a specific type of intensive chemotherapy that usually requires a long stay in the hospital. The app is currently available only in English, so you'll need to be comfortable understanding and speaking the language. This trial is open to all genders, and it’s important to note that patients with certain other types of leukemia or specific mental health issues may not be eligible. If you join, you can expect to use the app throughout your treatment, which is aimed at helping you manage your experience better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hospitalized patients (age \> 18 years) with a diagnosis of AML.
• • Initiating treatment with either intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen that typically requires a prolonged 3-6-week hospitalization and/or recovery.
• • Ability to comprehend and speak English as the digital apps are only available in English
• Exclusion Criteria:
• • Patients with a diagnosis of acute promyelocytic leukemia
• • Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.